A GNRH agonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Nafarelin (acetate)

Item No. 24070

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine) acetate
CAS Number
76932-60-0
Molecular Formula
C66H83N17O13 • XC2H4O2
Formula Weight
1322.5
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Slightly SolubleMethanol: Slightly SolubleWater: Slightly Soluble
SMILES
O=C(N[C@@H](CO)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@H](CC2=CC(C=CC=C3)=C3C=C2)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N4CCC[C@H]4C(NCC(N)=O)=O)=O)=O)=O)=O)=O)[C@@H](NC([C@@H](NC([C@@H]5CCC(N5)=O)=O)CC6=CNC=N6)=O)CC7=CNC8=C7C=CC=C8.OC(C)=O
InChi Code
InChI=1S/C66H83N17O13.C2H4O2/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46;1-2(3)4/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71);1H3,(H,3,4)/t46-,47-,48-,49-,50+,51-,52-,53-,54-;/m0./s1
InChi Key
GUJYDLHACHDKAJ-CFWZQLQRSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $63

    Add

    1 mg

    $118

    Add

    5 mg

    $454

    Add

    10 mg

    $783

    Add
    Product Description

    Nafarelin is an agonist of gonadotropin-releasing hormone (GNRH).1,2,3 It is a long-acting agent that, after an initial increase in sex hormone levels, decreases the level of circulating gonadotropins and sex hormones. In vivo, nafarelin (0.5-2.0 μg/kg, s.c.) reduces plasma levels of luteinizing hormone and testosterone (Item Nos. 15645 | ISO60154) as well as testicular volume, sperm count, sperm motility, and duration of ejaculation in male dogs.1 Nafarelin (32 μg/animal per day) inhibits estrus in female beagle dogs.2 It also reduces the volume of endometrial tissue in a rat model of endometriosis.3 Formulations containing nafarelin have been used in the treatment of endometriosis and central precocious puberty.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Vickery, B.H., McRae, G.I., Briones, W.V., et al. Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist. J. Androl. 6(1), 53-60 (1985).

    2. McRae, G.I., Roberts, B.B., Worden, A.C., et al. Long-term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist. J. Reprod. Fertil. 74(2), 389-397 (1985).

    3. Mizutani, T., Sakata, M., and Terakawa, N. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat. Int. J. Fertil. Menopausal Stud. 40(2), 106-111 (1995).